Severity
Moderate
ModerateClass IITerminated
FDA Food recall · Reported August 15, 2018
Genestra brand AFA-gen capsule 15 mg Niacin/ capsule 300 mg Blue Green Algae / capsule 2 capsules, twice daily Dietary supplement 90 capsules, White 150cc HDPE Bottle with Desiccant and white cap, packed as 12 bottles / shipper case
Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.
Seroyal International, a division of Atrium Innovations recalled Genestra brand AFA-gen capsule 15 mg Niacin/ capsule 300 mg Blue Green Algae / capsule … - a moderate-severity action.
Genestra brand AFA-gen capsule 15 mg Niacin/ capsule 300 mg Blue Green Algae / capsule … was recalled by Seroyal International, a division of Atrium Innovations in August 15, 2018. Reason: Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.. Check the official notice for the remedy. Verify recall #F-1756-2018 with the FDA Food before acting.
The recall
Seroyal International, a division of Atrium Innovations issued this moderate-severity FDA Food recall-Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification..
- Moderate
- severity level
- Class II
- classification
- August 15, 2018
- reported
Sourced from official FDA Food enforcement records. Verify recall #F-1756-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This FDA Food action (record #F-1756-2018) was formally reported on August 15, 2018, with the manufacturer initiating the action on July 27, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Seroyal International, a division of Atrium Innovations is listed as the recalling firm, operating out of Richmond Hill, Ontario. Federal records list the affected scope as 4,226 bottles (1691 Canada and 2535 USA).
The documented reason for this recall is: Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification. Distribution data in the federal record shows the product reached: Product was distributed throughout the United States and Canada (see attached document for list of Canadian consignees).. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 1 from FDA Food - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Drugs & Medications recalls over time
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
4,226 bottles (1691 Canada and 2535 USA)
Related Recalls
6
1 from same agency
Product description
Genestra brand AFA-gen capsule 15 mg Niacin/ capsule 300 mg Blue Green Algae / capsule 2 capsules, twice daily Dietary supplement 90 capsules, White 150cc HDPE Bottle with Desiccant and white cap, packed as 12 bottles / shipper case
Reason for recall
Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | F-1756-2018 |
| Date reported | August 15, 2018 |
| Date initiated | July 27, 2018 |
| Recalling firm | Seroyal International, a division of Atrium Innovations |
| Firm location | Richmond Hill, Ontario |
| Affected scope | 4,226 bottles (1691 Canada and 2535 USA) |
| Distribution | Product was distributed throughout the United States and Canada (see attached document for list of Canadian consignees). |
Profile values are sourced directly from the official FDA Food enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
- Check the recall number (F-1756-2018) and product description against the item you own. Search the archive
- Confirm the current status with FDA Food before acting, recall details can be updated.
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official FDA Food record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
Genestra brand AFA-gen capsule 15 mg Niacin/ capsule 300 mg Blue Green Algae / capsule 2 capsules, twice daily Dietary supplement 90 capsules, White 150cc HDPE Bottle with Desiccant and white cap, packed as 12 bottles / shipper case. Recalled by Seroyal International, a division of Atrium Innovations. Units affected: 4,226 bottles (1691 Canada and 2535 USA).
Why was this product recalled? ▼
Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.
Which agency issued this recall? ▼
This recall was issued by the FDA Food on August 15, 2018. Severity: Moderate. Recall number: F-1756-2018.
Where was the recalled product distributed? ▼
Distribution: Product was distributed throughout the United States and Canada (see attached document for list of Canadian consignees)..
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (F-1756-2018) against your product. Visit the official FDA Food website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
What are the health risks of consuming a recalled food product? ▼
Recalled food products may contain contaminants, undeclared allergens, or harmful bacteria such as Salmonella, Listeria, or E. coli. Consuming these products can cause foodborne illness ranging from mild gastrointestinal symptoms to serious conditions requiring hospitalization. If you have consumed a recalled food product and experience symptoms, contact your healthcare provider and report to the FDA via MedWatch.
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
FDA Drug Low
PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie c…
AbbVie Inc. · 2026-06-03
FDA Food Moderate
Vitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement, Net Wt. 8 FL Oz (237mL) Amber PET modern round 24-400 bot…
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
FDA Drug Moderate
Atomoxetine Capsules HCL, 10 mg Capsules in unit dose foil strip, strips are packed in cartons of 100, Rx Only, Pkg by:…
Safecor Health, LLC · 2026-05-27
FDA Drug Moderate
fentaNYL Citrate, Sterile CADD for Injection, 2,2500 mcg/50mL in Sterile Water, IntegraDose Compounding Services LLC, 3…
IntegraDose Compounding Services LLC · 2026-05-27
FDA Drug Moderate
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, …
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Food, reported August 15, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.